Rochester, MN Clinical Trials Report — July 2026

Rochester participants should act now if they match a study that is closing soon: 46 recruiting trials are expected to close within the next 90 days, including 3 that accept healthy volunteers. Rochester remains one of Minnesota’s strongest clinical research centers, with 1,108 recruiting trials across 139 research facilities.

July brought 9 new trial openings, down from 12 in May. Enrollment may end earlier than the projected closing date if a study reaches its participant target, so people with relevant diagnoses should review eligibility and contact local research teams promptly.

Closing-soon studies create the most immediate opportunities

The closing-soon pipeline includes cancer, heart rhythm, bladder, and nervous-system conditions. The listed areas include:

• Advanced solid tumor
• Anatomic stage I breast cancer, AJCC v8
• Anatomic stage II breast cancer, AJCC v8
• Atrial arrhythmia, atrial fibrillation, and atrial tachycardia
• Autonomic dysreflexia and autonomic imbalance
• Bladder absence and bladder dysfunction

Only 3 of the closing-soon trials accept healthy volunteers. Across Rochester, 118 recruiting studies currently include healthy-volunteer opportunities, but none of the 9 trials newly opened in July accept healthy volunteers. People without a diagnosed condition therefore have more options among already active studies than among this month’s new openings, and should confirm availability directly with each study team.

Major new Phase 2 and Phase 3 studies in Rochester

July’s new trials cover chronic and recurrent low back pain, congestive heart failure and heart failure, emergency care, genetic diseases, glioblastoma, liver cancer, liver metastases, and lung neoplasm. Three openings are classified as drug trials, with three categorized as other, two as procedures, one as biological, and one as a device study.

• NCT07735637 is AstraZeneca’s Phase 3 DURGA-6 study, comparing AZD0120 with autologous stem-cell transplantation as consolidation treatment for newly diagnosed multiple myeloma in transplant-eligible participants. The study plans to enroll 750 people and measures outcomes including progression-free survival and minimal residual disease-negative complete response.
• NCT07723469 is a Phase 3 SURGE Therapeutics study for people with clinical stage II-III triple-negative breast cancer undergoing breast-conserving surgery. It compares intraoperative SRG-514, whose active ingredient is ketorolac, with standard care alone and plans to enroll 400 participants.
• NCT07717437 is the DRAGON registry sponsored by Maastricht University Medical Center. It will enroll 350 participants with primarily unresectable liver cancer or liver metastases who underwent combined portal and hepatic vein embolization before resection.
• NCT07708961 is Mayo Clinic’s Phase 2 study of temozolomide with or without WSD0922-FU for EGFR-mutant, IDH-wildtype glioblastoma. It plans to enroll 60 participants and examines whether adding WSD0922-FU can slow disease progression.

Mayo Clinic sponsors 6 of the new trials, while AstraZeneca, Maastricht University Medical Center, and SURGE Therapeutics sponsor one each. The month’s sponsor mix is primarily academic or otherwise categorized research, with 7 studies listed as “other” and 2 classified as industry-sponsored. These openings add credible late-stage opportunities in multiple myeloma and breast cancer alongside Mayo-led Phase 2 oncology research.

Mayo facilities dominate local access

Rochester’s trial network is heavily concentrated within Mayo Clinic facilities. Mayo Clinic is listed with 423 trials, followed by Mayo Clinic in Rochester with 346 and Mayo Clinic Rochester with 78. Because clinical-trial databases may list the same health system under slightly different facility names, these figures should be viewed as separate database entries rather than automatically combined totals.

• Mayo Clinic — 423 trials
• Mayo Clinic in Rochester — 346 trials
• Mayo Clinic Rochester — 78 trials
• Research Site — 29 trials
• Mayo Clinic - Rochester — 29 trials
• Mayo Clinic Minnesota — 18 trials
• Mayo Clinic in Rochester, Minnesota — 13 trials
• Mayo Clinic, Rochester — 11 trials
• Mayo Clinic Cancer Center — 7 trials
• Clinical Trial Site — 5 trials
• Mayo Clinic (Data Collection Only) — 4 trials
• GSK Investigational Site — 4 trials

The concentration gives patients access to a broad mix of oncology, cardiovascular, neurological, pain, genetic-disease, and procedural research through Mayo-affiliated locations. The GSK Investigational Site also provides an industry research option, while smaller research-site listings may offer additional access depending on the condition and protocol.

Who may qualify this month

Among July’s new trials, 1 includes children and 9 include older adults. No new study is limited to women or men. None of the new openings accepts healthy volunteers, although the city has 118 healthy-volunteer studies recruiting overall. Eligibility can depend on diagnosis, disease stage, prior treatment, age, medications, test results, and willingness to attend study visits.

Patients with multiple myeloma, triple-negative breast cancer, glioblastoma, liver cancer, liver metastases, heart failure, or the other listed July conditions should ask about screening without waiting for the projected deadline. Healthy volunteers should search the broader Rochester pool now, particularly if they can meet study-specific time, medication, and health requirements.

Other Minnesota locations to consider

People able to travel can also look for studies in Minneapolis, which has 6 recruiting trials in the nearby-city data. Additional options are listed in Edina, Mankato, Maplewood, and Saint Paul, with 1 trial in each city. These locations may be useful when Rochester has no suitable protocol or when a study requires a particular specialty or testing site.

Rochester’s July pipeline is smaller than earlier in the year: monthly new-trial counts were 15 in February, 20 in March, 20 in April, 18 in May, 12 in June, and 9 in July. As summer progresses, patients should monitor Mayo-affiliated listings and nearby Minnesota sites for newly activated studies and replacement opportunities when closing trials reach their enrollment limits.